Archived AES Symposia 2005
Pediatric State of The Art - Seizures and Epilepsy Complicating Medical Conditions in Childhood
Program Length: 1 hrs 40 min
This years symposium will address advances in clinical management and translational research regarding acute provoked seizures and chronic epilepsy in children with complex medical conditions, such as congenital heart disease, oncological disorders, and organ transplantation.
At the conclusion of this activity, participants should be able to:
- Understand the etiology, pathophysiology and treatment of acute provoked seizures in children with congenital heart disease, CNS and non-CNS neoplasms, and organ transplantation
- Understand the etiology, pathophysiology and treatment of chronic epilepsy in these patients, including interactions between antiepileptic drugs and anti-arrhythmic drugs, chemotherapeutic agents, and immunosuppressive agents
- Recognize opportunities for translational research in this area, including neuro-protection pharmacology and immunology.
Child neurologists, adult neurologists, epileptologists, fellows, residents, nurse practitioners, and pharmacists.
Disclosure: It is the policy of the American Epilepsy Society that all faculty participating in continuing medical education activities are expected to disclose to the program audience (1) any real or apparent conflict(s) of interest related to the content of their presentation and (2) discussions of unlabeled or unapproved uses of drugs or medical devices. The American Epilepsy Society adheres to the ACCMEs Essential Areas and Policies regarding industry support of continuing medical education. Disclosure by faculty of commercial relationships, if any, and discussions of unlabeled or unapproved uses will be made.
Robert R. Clancy, M.D. has indicated he has received consulting fees from UCB Pharma and Abbott Laboratories. Dr. Clancy has also received fees for non-CME services from Abbott Laboratories and contracted research with Johnson and Johnson.
Dennis Dlugos, M.D. has indicated he has received consulting fees from Ortho-McNeil Neurologics, Inc., Eisai and UCB Pharma. Dr. Dlugos has also received fees for non-CME services from Ortho-McNeil Neurologics, Inc. and Eisai, Inc.
Benjamin Eidelman, M.D. indicated he has no real or apparent conflicts of interest to report.
Howard P. Goodkin, M.D., Ph.D. (liaison reviewer) has indicated he has no real or apparent conflicts of interest to report.
Anna Janss, M.D., Ph.D. has indicated she has no real or apparent conflicts of interest to report.
Mary L. Zupanc, M.D. has indicated she has received consulting fees from GlaxoSmithKline, UCB Pharma, Ortho McNeil Neurologics, Inc., Ovation and Medpointe. Dr. Zupanc has also received fees for non-CME services from GlaxoSmithKline, Novartis, Ortho McNeil Neurologics, Inc. and UCB Pharma.
Disclaimer: Opinions expressed with regard to unapproved uses of products are solely those of the faculty and are not endorsed by the American Epilepsy Society or any manufacturers of pharmaceuticals.